Write your message
Volume 7, Issue 6 (November - December 2022)                   J Obstet Gynecol Cancer Res 2022, 7(6): 587-588 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moradi B, Naybandi Atashi S, Shirali E. Size of Papillary Projection/Solid Component in O-RADS US Risk Stratification and Management System. J Obstet Gynecol Cancer Res 2022; 7 (6) :587-588
URL: http://jogcr.com/article-1-695-en.html
1- Department of Radiology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Radiology, Taleghani Hospital, Mazandaran University of Medical Sciences, Chalus, Iran
3- Department of Gynecologic Oncology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran , shirali.gyn@gmail.com
Abstract:   (425 Views)

Adnexal masses characterization is a really challenging issue and is essential for appropriate patient management. Ovarian Adnexal Reporting and Data System (O-RADS) is tone excellent standardized lexicons to provide practical uniform terms, definitions and measurements for describing and classifying ovarian masses.
In the first publication of O-RADS system, they noted that cystic lesions with maximum diameter of solid component of ≥7 mm, are at higher risk for malignancy. On the other hand, the number of papillary projections had nearly similar positive LR (2.2). Despite this and inclusion of the number of papillary projections in the final risk stratification system, the maximal size of solid part was not included and no cystic lesion with solid component could be categorized in O-RADS 3 category, and size of papillary projection make no change in malignancy risk stratification.

In conclusion, we propose that in O-RADS lexicon the use of maximal diameter of solid components (with 7 mm cut off point) along with number of papillary projections is helpful to categorize cystic ovarian mass lesions as auxiliary item for classifying risk of malignancy less than 10% to higher than 50% (O-RADS 3 to ORADS 5).

Full-Text [PDF 245 kb]   (61 Downloads) |   |   Full-Text (HTML)  (24 Views)  
Systematic Review: Letter to the Editor | Subject: Obstetrics and Gynecology
Received: 2022/04/28 | Accepted: 2022/06/11 | Published: 2022/09/9

References
1. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound‐based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31(6):681-90. [DOI:10.1002/uog.5365] [PMID]
2. Andreotti R, Timmerman D, Benacerraf B, Bennett G, Bourne T, Brown D, et al. Ovarian-adnexal reporting lexicon for ultrasound: a white paper of the ACR Ovarian-Adnexal Reporting and Data System Committee. J Am Coll Radiol. 2018;15(10):1415-29. [DOI:10.1016/j.jacr.2018.07.004] [PMID]
3. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000;16(5):500-5. [DOI:10.1046/j.1469-0705.2000.00287.x] [PMID]
4. Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, et al. O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology. 2020;294(1):168-85. [DOI:10.1148/radiol.2019191150] [PMID]
5. Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol. 2016;214(4):424-37. [DOI:10.1016/j.ajog.2016.01.007] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.